Ann: VivaGel BV secures TGA approval for prevention of BV, page-28

Interesting extract from a piece in the australian today.
SPL share price soooooo cheap.
Bring on the Nasal spray etc

"The first COVID-19 vaccine is unlikely to prevent people getting the disease and may only alleviate sufferers’ symptoms, scientists have told UK ministers.Government scientific advisers are prepared for the first vaccine that gains regulatory approval to be only partially effective and are considering how to explain to the country the need for caution as it is introduced.Boris Johnson has said previously that countries need to “work together to build an impregnable shield around all our people and that can only be achieved by developing and mass-producing a vaccine”.Read NextChris Whitty, the chief medical officer for England, believes that science will eventually “ride to the rescue” but that early inoculations are unlikely to protect everyone and the virus will continue to circulate.A jab that cuts the risk of people falling seriously ill would be a huge advance, reducing deaths in high-risk groups and lessening disruption to services such as cancer treatments.Experts say, though, that it would not enable an immediate return to normal life. Professor Whitty believes that a Covid vaccine comparable to the flu jab, which is 40 to 60 per cent effective, is realistic. The Oxford team leading the vaccine race has set a minimum target of 50 per cent protection.Britain's Prime Minister Boris Johnson washes immunologic assays during a visit to the Jenner Institute in Oxford, central England, where scientists are working on a vaccine. Picture: Kirsty Wigglesworth/AFPREAD MORE:Grim milestone as Covid marches on|Odds of 50-50 are enough for a jab|Plasma trial to boost immunity for health workers|What it would take for herd immunity to kill pandemic|Universities secure extra $6m for vaccine projects|Obese jeopardise vaccine success|Experts say that a vaccine that reduces symptomatic coronavirus cases by half would be an immensely valuable tool. However, they caution that people should not expect the first generation of vaccines to be a “silver bullet”.